Abstract
BACKGROUND: Kinesin family member 2A (KIF2A) is reported as an oncogene and a potential biomarker for progression and prognosis in several cancers such as cervical, ovarian, and gastric. However, its clinical value in basal-like breast cancer (BLBC) is unclear. This study aims to evaluate KIF2A expression and its correlation with clinical features and survival rates in BLBC patients. METHODS: KIF2A mRNA and protein expressions in tumor and adjacent tissues from 89 BLBC patients are assessed by reverse transcription-quantitative polymerase chain reaction and immunohistochemistry assays, respectively. RESULTS: Both KIF2A protein (p < 0.001) and mRNA expressions (p < 0.001) were higher in tumor than in adjacent tissue. Besides, tumor KIF2A protein expression was positively correlated with N (p = 0.028) and TNM (p = 0.014) stages; meanwhile, tumor KIF2A mRNA expression was positively correlated with N stage (p = 0.046), TNM stage (p = 0.006), and tumor size (p = 0.043). Additionally, both tumor KIF2A protein (p = 0.035) and mRNA (p = 0.039) high expressions were correlated with worse disease-free survival (DFS) but not with overall survival (both p > 0.05). Moreover, tumor KIF2A protein expression was higher in relapsed patients than in non-relapsed patients within 3 years (p = 0.015) and 5 years (p = 0.031), whereas no difference was found between the dead and survivors within 3 years (p = 0.057) or 5 years (p = 0.107). Lastly, after adjustment, tumor KIF2A mRNA high exhibited a trend that correlated with DFS but without statistical significance (p = 0.051). CONCLUSION: KIF2A correlates with more frequent lymph node metastasis and worse DFS in BLBC patients, shedding light on its potency as a biomarker for BLBC.